CAT No: L1602
CAS No: 62621-13-0
Synonyms/Alias: (S)-1-((3S,6S,9R,12S,15R,18S,21S)-3-((1H-imidazol-5-yl)methyl)-6-((1H-indol-3-yl)methyl)-21-(3-guanidinopropyl)-12-(4-hydroxybenzyl)-9-(hydroxymethyl)-15,18-diisobutyl-1,4,7,10,13,16,19-heptaoxo-1-((S)-5-oxopyrrolidin-2-yl)-2,5,8,11,14,17,20-heptaazadocosan-22-oyl)-N-ethylpyrrolidine-2-carboxamide; (D-Ser4)-Leuprolide ; 4-D-Serine-6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing hormone-releasing Factor (pig);(S)-N-Ethyl-1-(((S)-5-oxopyrrolidine-2-carbonyl)-L-histidyl-L-tryptophyl-D-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl)pyrrolidine-2-carboxamide; (Des-Gly10,D-Ser4,D-Leu6,Pro-NHEt9)-LHRH;62621-13-0;D-SER-LEUPROLIDE;ESP8322VGL;5-OXO-L-PROLYL-L-HISTIDYL-L-TRYPTOPHYL-D-SERYL-L-TYROSYL-D-LEUCYL-L-LEUCYL-L-ARGINYL-N-ETHYL-L-PROLINAMIDE;FD109744;(Des-Gly10,D-Ser4,D-Leu6,Pro-NHEt 9)-LHRH trifluoroacetate;Pyr-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt trifluoroacetate; Leuprolide (Leuprorelin) EP Impurity A
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C59H84N16O12 |
M.W/Mr. | 1209.4 |
Sequence | One Letter Code:XHWSYLLRP Three Letter Code:H-Pyr-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt |
InChI | InChI=1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47+,48-/m0/s1 |
InChI Key | GFIJNRVAKGFPGQ-WQVASJQXSA-N |
References | Impurity A of the Leuprorelin Ph. Eur. monograph. |
2. High fat diet and GLP-1 drugs induce pancreatic injury in mice
3. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
4. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
5. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.